Pomerantz LLP has filed a class action lawsuit against Insulet Corporation and certain officers on behalf of investors who purchased Insulet securities between February 21, 2025 and May 26, 2026. The suit, filed in the US District Court for the District of Massachusetts, alleges that the company made false and misleading statements about its manufacturing controls and product safety. The complaint points to two voluntary medical device corrections disclosed in 2026—one on March 12 for Omnipod 5 Pods and another on May 26 for Omnipod 5, Omnipod Dash, and Omnipod Insulin Management System Pods—which caused the stock to drop 6.88% and 5.07% respectively. Investors have until August 31, 2026 to seek appointment as lead plaintiff.
Insulet CorporationClass action lawsuit alleging false statements about manufacturing controls and product safety, with two product corrections causing stock drops.